Brazil pharma market driven by generic medicines

31 October 2011

According to the Ministry of Health, the Brazilian pharmaceutical market has grown to $28 billion annually, backed strongly by the sale of generics medicines. It is noted that, since 1999, Brazil has accelerated its growth in the production of generic medicines as a result of a government program with this aim.

Currently, there are about 540 registered pharmaceutical companies in Brazil, 90 of which are producers of generic medicines.

Generics account for 20.6% of sales in units throughout the Brazilian pharmaceutical market. However, the news illustrates that, despite advances in the marketing of generic medicines, foreign multinational manufacturing drugs are still are more engaged in the production of novel drugs because of the large investment in research they put in R&D, notes a posting on the IP Tango blog site, asking: is this a negative criticism?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >